{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:41:33Z","timestamp":1790138493794,"version":"4.0.1"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008884","name":"Edward P Evans Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","award":["K08HL171883"],"award-info":[{"award-number":["K08HL171883"]}],"id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1053\/j.seminhematol.2026.05.008","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T23:54:00Z","timestamp":1780530840000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies"],"prefix":"10.1053","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8726-6212","authenticated-orcid":false,"given":"Lachelle D.","family":"Weeks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2026.05.008_bib0001","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJMra1510865","article-title":"Sickle cell disease","volume":"376","author":"Piel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0002","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.2022.10233","article-title":"Sickle cell disease: a review","volume":"328","author":"Kavanagh","year":"2022","journal-title":"JAMA"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0003","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/ejh.14360","article-title":"The mortality of adults with sickle cell disease at a comprehensive sickle cell center","volume":"114","author":"Afranie-Sakyi","year":"2025","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0004","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/bloodadvances.2024013926","article-title":"Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease","volume":"9","author":"Walters","year":"2025","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0005","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1016\/S2352-3026(19)30154-1","article-title":"Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study","volume":"6","author":"Eapen","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0006","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1200\/JCO.22.01203","article-title":"Secondary neoplasms after hematopoietic cell transplant for sickle cell disease","volume":"41","author":"Eapen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0007","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1182\/blood.2022017960","article-title":"Increased incidence of hematologic malignancies in SCD after HCT in adults with graft failure and mixed chimerism","volume":"140","author":"Lawal","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0008","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/ajh.27627","article-title":"Recipient cells are the source of hematologic malignancies after graft failure and mixed chimerism in adults with SCD","volume":"100","author":"Ali","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0009","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1182\/bloodadvances.2019001330","article-title":"Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease","volume":"4","author":"Hsieh","year":"2020","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0010","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2109167","article-title":"Acute myeloid leukemia case after gene therapy for sickle cell disease","volume":"386","author":"Goyal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0011","first-page":"1185","article-title":"Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation","volume":"135","author":"Ghannam","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0012","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2017-05-783233","article-title":"Increased risk of leukemia among sickle cell disease patients in California","volume":"130","author":"Brunson","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0013","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/0141076816651037","article-title":"Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage study","volume":"109","author":"Seminog","year":"2016","journal-title":"J R Soc Med"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0014","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1182\/blood.2021011121","article-title":"Clonal hematopoiesis in sickle cell disease","volume":"138","author":"Pincez","year":"2021","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0015","doi-asserted-by":"crossref","DOI":"10.1172\/JCI156060","article-title":"Clonal hematopoiesis in sickle cell disease","volume":"132","author":"Liggett","year":"2022","journal-title":"J Clin Invest"},{"issue":"13","key":"10.1053\/j.seminhematol.2026.05.008_bib0016","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1182\/blood.2025030898","article-title":"Increased prevalence of clonal hematopoiesis in children with sickle cell disease","volume":"147","author":"Ulloa","year":"2025","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.05.008_bib0017","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2025-8","article-title":"Sickle cell disease is associated with early-onset clonal hematopoiesis involving DNA damage response pathway mutations","volume":"146","author":"Weeks","year":"2025","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0018","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/ajh.23683","article-title":"Factors associated with survival in a contemporary adult sickle cell disease cohort","volume":"89","author":"Elmariah","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0019","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1182\/blood-2016-05-716910","article-title":"Survival in adults with sickle cell disease in a high-income setting","volume":"128","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0020","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/15353702211068522","article-title":"Sickle cell disease as an accelerated aging syndrome","volume":"247","author":"Idris","year":"2022","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0021","first-page":"13225","article-title":"Adolescents and young adults with sickle cell disease exhibit accelerated aging with elevated T-cell p16(INK4a) expression","volume":"16","author":"Wilson","year":"2024","journal-title":"Aging (Albany NY)"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0022","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/bloodadvances.2023011188","article-title":"Characterizing epigenetic aging in an adult sickle cell disease cohort","volume":"8","author":"L\u00ea","year":"2024","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0023","doi-asserted-by":"crossref","DOI":"10.1093\/gerona\/glae230","article-title":"Black Americans with sickle cell disease (SCD) demonstrate accelerated epigenetic pace of aging compared to Black Americans without SCD","volume":"79","author":"Garrett","year":"2024","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0024","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/s41379-019-0325-6","article-title":"Myeloid neoplasms in the setting of sickle cell disease: an intrinsic association with the underlying condition rather than a coincidence; report of 4 cases and review of the literature","volume":"32","author":"Li","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0025","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00277-020-03940-8","article-title":"Usefulness of azacitidine therapy in a sickle cell disease patient with myelodysplastic syndrome","volume":"99","author":"De Luna","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0026","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/ajh.23768","article-title":"Peripheral blood features of acute myeloid leukemia with myelodysplasia-related changes developing in a patient with sickle cell anemia","volume":"89","author":"Zemenides","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0027","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4137\/CMO.S8810","article-title":"Development of myelodysplastic syndrome and acute myeloid leukemia 15 years after hydroxyurea use in a patient with sickle cell anemia","volume":"6","author":"Baz","year":"2012","journal-title":"Clin Med Insights Oncol"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0028","doi-asserted-by":"crossref","first-page":"E131","DOI":"10.1002\/ajh.24010","article-title":"Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia","volume":"90","author":"Aumont","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0029","doi-asserted-by":"crossref","first-page":"925","DOI":"10.7326\/0003-4819-133-11-200012050-00029","article-title":"Acute leukemia in a patient with sickle-cell anemia treated with hydroxyurea","volume":"133","author":"Wilson","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0030","doi-asserted-by":"crossref","first-page":"722","DOI":"10.7326\/0003-4819-155-10-201111150-00024","article-title":"Therapy-related acute myelogenous leukemia in a hydroxyurea-treated patient with sickle cell anemia","volume":"155","author":"Taylor","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0031","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/10428194.2017.1324158","article-title":"Accelerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell disease","volume":"59","author":"Janakiram","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0032","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/ajh.2830210212","article-title":"Hematologic malignancy in sickle cell disease: report of four cases and review of the literature","volume":"21","author":"Stricker","year":"1986","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0033","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13641","article-title":"Haploidentical bone marrow transplantation in a patient with sickle cell disease and acute myeloid leukemia","volume":"24","author":"Chellapandian","year":"2020","journal-title":"Pediatr Transpl"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0034","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1080\/15384047.2019.1647055","article-title":"Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient","volume":"20","author":"Regan","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0035","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1056\/NEJM198409203111207","article-title":"Bone-marrow transplantation in a patient with sickle-cell anemia","volume":"311","author":"Johnson","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0036","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41375-023-01864-6","article-title":"Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective","volume":"37","author":"Moreno Berggren","year":"2023","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0037","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2023-172992","article-title":"Myeloid neoplasia in patients with hereditary hemoglobinopathies and hemolytic anemias (HHAs)","volume":"142","author":"Osei","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0038","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/jama.289.13.1645","article-title":"Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment","volume":"289","author":"Steinberg","year":"2003","journal-title":"JAMA"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0039","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2009-05-221333","article-title":"The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)","volume":"115","author":"Voskaridou","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.05.008_bib0040","doi-asserted-by":"crossref","DOI":"10.1172\/JCI158251","article-title":"The hematopoietic saga of clonality in sickle cell disease","volume":"132","author":"Stonestrom","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0041","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/pbc.22144","article-title":"Malignancies in patients with beta-thalassemia major and beta-thalassemia intermedia: a multicenter study in Iran","volume":"53","author":"Karimi","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0042","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5045\/br.2013.48.2.149","article-title":"Hematological malignancies complicating \u03b2-thalassemia syndromes: a single center experience","volume":"48","author":"Alavi","year":"2013","journal-title":"Blood Res"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0043","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1182\/blood.2023022222","article-title":"Causes and consequences of clonal hematopoiesis","volume":"142","author":"Weeks","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0044","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41586-022-04785-z","article-title":"The longitudinal dynamics and natural history of clonal haematopoiesis","volume":"606","author":"Fabre","year":"2022","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0045","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0046","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/j.seminhematol.2024.01.005","article-title":"Clonal hematopoiesis in children with predisposing conditions","volume":"61","author":"Attardi","year":"2024","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0047","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0048","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0049","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.celrep.2015.02.005","article-title":"Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis","volume":"10","author":"McKerrell","year":"2015","journal-title":"Cell Rep"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0050","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0051","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12484","article-title":"Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults","volume":"7","author":"Young","year":"2016","journal-title":"Nat Commun"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0052","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41586-020-2819-2","article-title":"Inherited causes of clonal haematopoiesis in 97,691 whole genomes","volume":"586","author":"Bick","year":"2020","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0053","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1001\/jamaoncol.2021.4664","article-title":"Preexisting TP53-variant clonal hematopoiesis and risk of secondary myeloid neoplasms in patients with high-grade ovarian cancer treated with Rucaparib","volume":"7","author":"Kwan","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0054","doi-asserted-by":"crossref","first-page":"7248","DOI":"10.1038\/s41598-022-09604-z","article-title":"Genetics of smoking and risk of clonal hematopoiesis","volume":"12","author":"Levin","year":"2022","journal-title":"Sci Rep"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2018.10.013","article-title":"Inhibition of inflammatory signaling in Tet2 mutant preleukemic cells mitigates stress-induced abnormalities and clonal hematopoiesis","volume":"23","author":"Cai","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0056","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.bjc.6604935","article-title":"Risks of myeloid malignancies in patients with autoimmune conditions","volume":"100","author":"Anderson","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0057","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41588-023-01472-1","article-title":"Multiparameter prediction of myeloid neoplasia risk","volume":"55","author":"Gu","year":"2023","journal-title":"Nat Genet"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.05.008_bib0058","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200310","article-title":"Prediction of risk for myeloid malignancy in clonal hematopoiesis","volume":"2","author":"Weeks","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0059","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.2024024756","article-title":"Risk prediction for clonal cytopenia: multicenter real-world evidence","volume":"144","author":"Xie","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0060","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","article-title":"Prediction of acute myeloid leukaemia risk in healthy individuals","volume":"559","author":"Abelson","year":"2018","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0061","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","article-title":"Somatic mutations precede acute myeloid leukemia years before diagnosis","volume":"24","author":"Desai","year":"2018","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0062","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0063","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.51927","article-title":"Clonal hematopoiesis risk score and all-cause and cardiovascular mortality in older adults","volume":"7","author":"Saadatagah","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0064","first-page":"1623","article-title":"What to tell your patient with clonal hematopoiesis and why: insights from 2 specialized clinics","volume":"136","author":"Steensma","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0065","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1182\/bloodadvances.2023011510","article-title":"Clonal hematopoiesis and inflammation in the vasculature: CHIVE, a prospective, longitudinal clonal hematopoiesis cohort and biorepository","volume":"8","author":"Shannon","year":"2024","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0066","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","article-title":"Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma","volume":"35","author":"Gibson","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0067","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.3324\/haematol.2019.216788","article-title":"Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease","volume":"104","author":"Cappelli","year":"2019","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0068","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjh.17311","article-title":"Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres","volume":"192","author":"Alzahrani","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0069","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41409-017-0077-1","article-title":"Haploidentical hematopoietic stem cell transplant for patients with sickle cell disease using thiotepa, fludarabine, thymoglobulin, low dose cyclophosphamide, 200 cGy tbi and post transplant cyclophosphamide","volume":"53","author":"Frangoul","year":"2018","journal-title":"Bone Marrow Transpl"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0070","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.bbmt.2018.03.031","article-title":"Haploidentical peripheral blood stem cell transplantation demonstrates stable engraftment in adults with sickle cell disease","volume":"24","author":"Saraf","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0071","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.bbmt.2020.05.005","article-title":"CTLA4Ig in an extended schedule along with Sirolimus improves outcome with a distinct pattern of immune reconstitution following post-transplantation cyclophosphamide-based haploidentical transplantation for hemoglobinopathies","volume":"26","author":"Jaiswal","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0072","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S2352-3026(19)30031-6","article-title":"Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0073","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/bloodadvances.2016002972","article-title":"Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT","volume":"1","author":"Fitzhugh","year":"2017","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0074","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1200\/JCO.21.02286","article-title":"Donor clonal hematopoiesis and recipient outcomes after transplantation","volume":"40","author":"Gibson","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0075","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41375-018-0218-6","article-title":"European experience and risk factor analysis of donor cell-derived leukaemias\/MDS following haematopoietic cell transplantation","volume":"33","author":"Engel","year":"2019","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0076","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/leu.2016.63","article-title":"Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation","volume":"30","author":"Gondek","year":"2016","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0077","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bmt.1701291","article-title":"Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium","volume":"22","author":"Vermylen","year":"1998","journal-title":"Bone Marrow Transpl"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0078","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1182\/blood.2021011488","article-title":"Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither","volume":"138","author":"Jones","year":"2021","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0079","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1038\/s41591-023-02636-6","article-title":"Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease","volume":"29","author":"Spencer Chapman","year":"2023","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0080","doi-asserted-by":"crossref","first-page":"5148","DOI":"10.1182\/bloodadvances.2025017215","article-title":"Ethical considerations for hematologic precursor conditions","volume":"9","author":"Blackstone","year":"2025","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0081","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1182\/bloodadvances.2022008376","article-title":"Patient perspectives on testing for clonal hematopoiesis of indeterminate potential","volume":"6","author":"Sella","year":"2022","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0082","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1038\/s41591-021-01521-4","article-title":"Distinction of lymphoid and myeloid clonal hematopoiesis","volume":"27","author":"Niroula","year":"2021","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2026.05.008_bib0083","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41467-020-20565-7","article-title":"Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis","volume":"12","author":"Gao","year":"2021","journal-title":"Nat Commun"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:19:22Z","timestamp":1785885562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196326000491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":83,"alternative-id":["S0037196326000491"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.05.008","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}